GleamWall
中文EN

DCOY Decoy Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1615219 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-11,102.9%
ROA-222.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets48.3%
Debt / equity0.00x
Current ratio1.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio-98.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$307,430$227,629——$0$0——
R&D expense$1.57M$1.30M$749,813$114,429$61,826$116,383$75,532$175,344
SG&A expense$1.75M$1.33M$1.53M$402,167$833,304$849,182$1.64M$1.31M
Operating income-$3.01M-$2.63M-$2.28M-$9.03M-$895,130-$965,565-$1.72M-$1.49M
Net income-$2.99M-$2.37M-$2.22M-$8.98M-$873,467-$957,825-$1.71M-$1.46M
EBITDA-$2.99M-$2.62M-$2.28M-$9.03M-$894,024-$964,459-$1.72M-$1.49M
EPS (basic)-3.53-4.46-4.18—-21.76-81.21-240.07—
EPS (diluted)-3.53-4.46-4.18—-21.76-81.21-240.07—
Weighted avg. shares (diluted)845,439531,968531,968—40,13211,7947,121—
Balance sheet
Cash & equivalents$8.17M$8.29M$7.82M$10.71M$4.81M$794,886$1.80M$2.43M
Current assets$8.38M$8.57M$8.36M$10.99M$6.06M$1.36M$2.31M$2.99M
PP&E, net$385,118$399,077$35,741$40,559———$0
Total assets$8.79M$9.00M$8.42M$11.06M$6.10M$1.39M$2.34M$3.02M
Current liabilities$4.25M$4.68M$4.55M$5.17M———$1.51M
Total liabilities$4.25M$4.68M$4.55M$5.17M$1.85M$2.22M$2.28M$1.51M
Shareholders' equity$4.55M$4.32M$3.88M$5.89M-$4.25M-$829,724$61,866$1.51M
Shares outstanding2.39M531,968531,968531,968944,4912.13M2.08M96,077
Cash flow statement
Operating cash flow-$2.59M-$2.65M-$2.89M-$1.14M-$1.65M-$862,297-$1.18M-$742,518
Investing cash flow-$79,366——$964,735-$200,000——$0
Financing cash flow$2.55M$3.16M$0$6.07M$5.86M-$141,197$545,566-$106,983
Depreciation & amortization$24,863$13,632$5,924$3,833$1,106$1,106$1,106$1,106
Stock-based compensation$253,474$206,177$213,044$139,523$22,846$23,155$33,534$51,045

Free plan shows the latest 8 periods; Pro shows all 50 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.